Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Aprindine Therapy for Refractory Ventricular Tachycardia

Aprindine Therapy for Refractory Ventricular Tachycardia Abstract • Aprindine hydrochloride has been extensively used in Europe for the management of ventricular and supraventricular arrhythmias. Success has been achieved even in those cases that have proven refractory to standard antiarrhythmic agents. In this report, we describe our experience with aprindine therapy in seven patients with ventricular tachycardia in whom standard antiarrhythmic agents had proven either ineffective or had caused intolerable side effects. Aprindine was effective in five cases, and it failed in two. Neurologic side effects, although common, were easily controlled with adjustment of the dose. Agranulocytosis, a rare but serious side effect, was encountered in one of our patients. Relevant literature on aprindine is reviewed. (Arch Intern Med 1983;143:229-232) References 1. Singh BN, Collett JT, Chew YCC: New perspectives in the pharmacologic therapy of cardiac arrhythmias. Prog Cardiovasc Dis 1980;22: 243-293.Crossref 2. Georges A, Hosslet A, Duvernay G: Pharmacologic evaluation of aprindine (AC 1802): A new antiarrhythmic agent. Acta Cardiol 1973;28: 166-191. 3. Bollen G, Enderle J: Preliminary experience in the treatment of cardiac arrhythmias with aprindine. Acta Cardiol Suppl 1974;18:355-360. 4. Breithardt G, Gleichmann U, Seipel L: Long-term oral antiarrhythmic therapy with aprindine. Acta Cardiol Suppl 1974;18:341-353. 5. Fasola AF, Noble RJ, Zipes DP: Treatment of recurrent ventricular tachycardia and fibrillation with aprindine. Am J Cardiol 1977;39:903-909.Crossref 6. Kesteloot H: General aspects of antiarrhythmic treatment with aprindine. Acta Cardiol Suppl 1979;18:303-316. 7. Van Durme JP, Rousseau M, Mbuyamba P: Treatment of ventricular dysrhythmias with a new drug, aprindine (AC 1802). Acta Cardiol Suppl 1974;18:335-340. 8. Wellens HJ, Bar FW, Lie KI: The value of the electrocardiogram in the differential diagnosis of a tachycardia with a widened QRS complex. Am J Med 1978;64:27-33.Crossref 9. Horowitz LN, Josephson ME, Farshidi A, et al: Recurrent sustained ventricular tachycardia: III. Role of the electrophysiologic study in selection of antiarrhythmic regimen. Circulation 1978;58:986-999.Crossref 10. Danilo P: Aprindine. Am Heart J 1979;97:119-124.Crossref 11. Zipes DP, Troup PJ: New antiarrhythmic agents. Am J Cardiol 1979;41:1005-1034.Crossref 12. Fasola AF, Carmichael R: The pharmacology and clinical evaluation of aprindine: A new antiarrhythmic agent. Acta Cardiol Suppl 1974;18:317-333. 13. Palma-Gamiz JL, Boedo C, Lopez-Pujol FJ, et al: Etude clinique d'un nouvel: Anti-arythmique: Aprindine. Acta Cardiol Suppl 1974;18:361-368. 14. Elewaut A, Van Durme JP, Goethals L, et al: Aprindine-induced liver injury. Acta Gastroenterol Belg 1977;40:236-243. 15. Herlong H, Reid PR, Boitnot JK, et al: Aprindine hepatitis. Ann Intern Med 1978;89:359.Crossref 16. Stoel I, Haemeijer F: Aprindine: A review. Eur J Cardiol 1980;1:147-156. 17. Van Leeuwan R, Meyboom RHB: Agranulocytosis and aprindine. Lancet 1976;2:1137.Crossref 18. Baedeker W, Rastetter J: Granulozytose nach aprindin-Behandlung. MMW 1977;119:1047-1048. 19. Bodenheimer HC Jr, Samarel AM: Agranulocytosis associated with aprindine therapy. Arch Intern Med 1979;139:1181-1182.Crossref 20. Greene HL, Reid PR, Schaeffer AH: Prolongation of cardiac conduction times by intravenous aprindine in man. Am J Cardiol 1978;42:1002-1006.Crossref 21. Strassberg B, Palileo E, Prechel D, et al: Ventricular tachycardia: Prediction of response to oral aprindine with intravenous aprindine. Am J Cardiol 1981;47:676-682.Crossref http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Internal Medicine American Medical Association

Aprindine Therapy for Refractory Ventricular Tachycardia

Loading next page...
 
/lp/american-medical-association/aprindine-therapy-for-refractory-ventricular-tachycardia-PenLvJ6wP7
Publisher
American Medical Association
Copyright
Copyright © 1983 American Medical Association. All Rights Reserved.
ISSN
0003-9926
eISSN
1538-3679
DOI
10.1001/archinte.1983.00350020047010
Publisher site
See Article on Publisher Site

Abstract

Abstract • Aprindine hydrochloride has been extensively used in Europe for the management of ventricular and supraventricular arrhythmias. Success has been achieved even in those cases that have proven refractory to standard antiarrhythmic agents. In this report, we describe our experience with aprindine therapy in seven patients with ventricular tachycardia in whom standard antiarrhythmic agents had proven either ineffective or had caused intolerable side effects. Aprindine was effective in five cases, and it failed in two. Neurologic side effects, although common, were easily controlled with adjustment of the dose. Agranulocytosis, a rare but serious side effect, was encountered in one of our patients. Relevant literature on aprindine is reviewed. (Arch Intern Med 1983;143:229-232) References 1. Singh BN, Collett JT, Chew YCC: New perspectives in the pharmacologic therapy of cardiac arrhythmias. Prog Cardiovasc Dis 1980;22: 243-293.Crossref 2. Georges A, Hosslet A, Duvernay G: Pharmacologic evaluation of aprindine (AC 1802): A new antiarrhythmic agent. Acta Cardiol 1973;28: 166-191. 3. Bollen G, Enderle J: Preliminary experience in the treatment of cardiac arrhythmias with aprindine. Acta Cardiol Suppl 1974;18:355-360. 4. Breithardt G, Gleichmann U, Seipel L: Long-term oral antiarrhythmic therapy with aprindine. Acta Cardiol Suppl 1974;18:341-353. 5. Fasola AF, Noble RJ, Zipes DP: Treatment of recurrent ventricular tachycardia and fibrillation with aprindine. Am J Cardiol 1977;39:903-909.Crossref 6. Kesteloot H: General aspects of antiarrhythmic treatment with aprindine. Acta Cardiol Suppl 1979;18:303-316. 7. Van Durme JP, Rousseau M, Mbuyamba P: Treatment of ventricular dysrhythmias with a new drug, aprindine (AC 1802). Acta Cardiol Suppl 1974;18:335-340. 8. Wellens HJ, Bar FW, Lie KI: The value of the electrocardiogram in the differential diagnosis of a tachycardia with a widened QRS complex. Am J Med 1978;64:27-33.Crossref 9. Horowitz LN, Josephson ME, Farshidi A, et al: Recurrent sustained ventricular tachycardia: III. Role of the electrophysiologic study in selection of antiarrhythmic regimen. Circulation 1978;58:986-999.Crossref 10. Danilo P: Aprindine. Am Heart J 1979;97:119-124.Crossref 11. Zipes DP, Troup PJ: New antiarrhythmic agents. Am J Cardiol 1979;41:1005-1034.Crossref 12. Fasola AF, Carmichael R: The pharmacology and clinical evaluation of aprindine: A new antiarrhythmic agent. Acta Cardiol Suppl 1974;18:317-333. 13. Palma-Gamiz JL, Boedo C, Lopez-Pujol FJ, et al: Etude clinique d'un nouvel: Anti-arythmique: Aprindine. Acta Cardiol Suppl 1974;18:361-368. 14. Elewaut A, Van Durme JP, Goethals L, et al: Aprindine-induced liver injury. Acta Gastroenterol Belg 1977;40:236-243. 15. Herlong H, Reid PR, Boitnot JK, et al: Aprindine hepatitis. Ann Intern Med 1978;89:359.Crossref 16. Stoel I, Haemeijer F: Aprindine: A review. Eur J Cardiol 1980;1:147-156. 17. Van Leeuwan R, Meyboom RHB: Agranulocytosis and aprindine. Lancet 1976;2:1137.Crossref 18. Baedeker W, Rastetter J: Granulozytose nach aprindin-Behandlung. MMW 1977;119:1047-1048. 19. Bodenheimer HC Jr, Samarel AM: Agranulocytosis associated with aprindine therapy. Arch Intern Med 1979;139:1181-1182.Crossref 20. Greene HL, Reid PR, Schaeffer AH: Prolongation of cardiac conduction times by intravenous aprindine in man. Am J Cardiol 1978;42:1002-1006.Crossref 21. Strassberg B, Palileo E, Prechel D, et al: Ventricular tachycardia: Prediction of response to oral aprindine with intravenous aprindine. Am J Cardiol 1981;47:676-682.Crossref

Journal

Archives of Internal MedicineAmerican Medical Association

Published: Feb 1, 1983

References